Skip to main content

and
  1. Article

    Open Access

    Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

    Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A p...

    Pardeep S. Jhund, Toru Kondo, Jawad H. Butt, Kieran F. Docherty in Nature Medicine (2022)

  2. Article

    Open Access

    A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials

    Win statistics offer a new approach to the analysis of outcomes in clinical trials, allowing the combination of time-to-event and longitudinal measurements and taking into account the clinical importance of th...

    Toru Kondo, Pardeep S. Jhund, Samvel B. Gasparyan, Mingming Yang in Nature Medicine (2024)